Reimbursement of the atopic dermatitis treatment ‘Dupixent’ is expected to be expanded for pediatric and adolescent patients from April.

According to sources from related industries, Sanofi-Aventis Korea recently concluded a drug price negotiation with the National Health Insurance Service for the low dose (200mg) of Dupixent (dupilumab). Thus, Dupixent will be presented to the Health Insurance Policy Deliberation Committee tomorrow (23rd).

On the 23rd, JAK inhibitors such as Abbvie Korea’s ‘Rinvoq (upadacitinib)’ and Pfizer Korea’s ‘Cibinqo (abrocitinib)’ will also be discussed. Unless otherwise, treatment options for pediatric atopic dermatitis patients will be drastically expa